Skip to main content
. 2007 Dec;1(4):377–392.

Table 3.

Phase II oral vorinostat: intent to treat response of 24% (8/33)

400 mg qd (n = 13) 300 mg bid × 3–5 d/wk (n = 11) 300 mg bid × 2w 400 mg qd (n = 9)
Partial response 4 (31%) 1 (9%) 3 (33%)
Marked (patients) 2 1 3
Median PR duration (range/weeks) 15 (8–24) 16 (8–24) 13 (3–21)
Mean time to PR (weeks) 11 4 11
LN regression at 4 wks (patients) 7 of 9 3 of 8 5 of 9
>50%↓ pruritus (patients) 9 of 11 8 of 12 4 of 8

Abbreviations: LN, lymph node; PR, partial response.